TAK1/MAP3K7 Recombinant Antibody
Applications
Reactivity
| Overview | |
| Catalog # | bsm-54071R-100uL |
| Product Name | TAK1/MAP3K7 Recombinant Antibody |
| Applications |
WB
IF(IHC-P)
IF(ICC)
IHC-P
FCM
|
| Reactivity | Human, Mouse |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | C terminal Human MAP3K7 |
| Clonality | Monoclonal |
| Clone # | 11A1 |
| Isotype | IgG |
| Concentration | Lot Dependent |
| Purification | purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4℃. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 6885 |
| Swiss Prot | O43318 |
| Synonyms | Mitogen-activated protein kinase kinase kinase 7, Transforming growth factor-beta-activated kinase 1, TGF-beta-activated kinase 1, MAP3K7, TAK1 |
| Background | Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(ICC) | 1:50-200 |
| IHC-P | 1:50-200 |
| FCM | 10ul/10^6 cells in 100ul |
Frequently asked questions
Which applications is TAK1/MAP3K7 Recombinant Antibody (bsm-54071R) validated for, and at what dilution?
bsm-54071R is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(ICC) (1:50-200); IHC-P (1:50-200); FCM (10ul/10^6 cells in 100ul). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does TAK1/MAP3K7 Recombinant Antibody (bsm-54071R) react with?
Tested reactivity: Human, Mouse.
How should bsm-54071R be stored?
Shipped at 4℃. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. Storage buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise TAK1/MAP3K7 Recombinant Antibody (bsm-54071R)?
C terminal Human MAP3K7